Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions... Show more
PGNY moved above its 50-day moving average on June 27, 2025 date and that indicates a change from a downward trend to an upward trend. In of 48 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where PGNY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 27, 2025. You may want to consider a long position or call options on PGNY as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for PGNY just turned positive on June 27, 2025. Looking at past instances where PGNY's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PGNY advanced for three days, in of 325 cases, the price rose further within the following month. The odds of a continued upward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGNY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PGNY broke above its upper Bollinger Band on June 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a medical device company, which engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools